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Objectives: The aim of this study was to review the requirements for the
reimbursement of biosimilars and to compare the reimbursement status, market share,
and reimbursement costs of biosimilars in selected Central and Eastern European (CEE)
countries.
Methods: A questionnaire-based survey was conducted between November 2016
and January 2017 among experts from the following CEE countries: Bulgaria, Czech
Republic, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania.
The requirements for the pricing and reimbursement of biosimilars were reviewed for
each country. Data on the extent of reimbursement of biologic drugs (separately for
original products and biosimilars) in the years 2014 and 2015 were also collected for
each country, along with data on the total pharmaceutical and total public health care
budgets.
Results: Our survey revealed that no specific criteria were applied for the pricing and
reimbursement of biosimilars in the selected CEE countries; the price of biosimilars
was usually reduced compared with original drugs and specific price discounts were
common. Substitution and interchangeability were generally allowed, although in most
countries they were at the discretion of the physician after a clinical assessment. Original
biologic drugs and the corresponding biosimilars were usually in the same homogeneous
group, and internal reference pricing was usually employed. The reimbursement rate
of biosimilars in the majority of the countries was the same and amounted to 100%.
Generally, the higher shares of expenditures were shown for the reimbursement of original
drugs than for biosimilars, except for filgrastim, somatropin, and epoetin (alfa and zeta).
The shares of expenditures on the reimbursement of biosimilar products ranged from
8.0% in Estonia in 2014 to 32.4% in Lithuania in 2015, and generally increased in 2015.
The share of expenditures on reimbursement of biosimilars in the total pharmaceutical
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budget differed between the countries, with the highest observed value for Slovakia and
Hungary and the lowest—for Croatia.
Conclusions: The requirements for the pricing and reimbursement of biosimilar
products as well as the access of patients to biologic treatment do not differ significantly
between the considered CEE countries. Biosimilar drugs significantly influence the
reimbursement systems of these countries, and the expenditure on the reimbursement
of biosimilars is increasing as they are becoming more accessible to patients.
Keywords: biosimilar pharmaceuticals, pricing, reimbursement, original products, interchangeability
INTRODUCTION
Biologics are complex, protein-based drugs used in various
diseases, including diabetes (insulins), inflammatory diseases,
and cancers. They are produced in living organisms, such as
bacteria, yeast, animals, or plants. The introduction of biologics
has been a major breakthrough in the treatment of numerous
conditions, but the drugs are often expensive (Mulcahy et al.,
2014; Ornes, 2015). A biosimilar is a biological product that is
approved for use on the basis of high similarity to an original
biological product, known as a reference product or originator
drug, and that shows no clinically meaningful differences in
terms of safety and effectiveness from the original product.
Only minor differences in clinically inactive components are
acceptable, and a biosimilar provides the same clinical benefits
as an original drug that is already on the market. Pharmaceutical
companies can release biosimilar products after a patent on a
particular biologic drug has expired. Over the past decade, over
80 biologic molecules have been launched globally (IMS, 2016).
By 2020 the global market of biologic medicinal products is
projected to exceed 390 billion USD and its value is estimated
to account for up to 28% of the global pharmaceutical market.
By this time, biosimilar products will have the potential to enter
markets as follow-ons to a number of key biologics which have
the current sales of more than 40 billion EUR. Almost 50 distinct
biosimilars are currently in development (IMS, 2016). Biosimilars
have the potential to reduce the cost of treatment similarly to
generics in the case of traditional, chemically synthesized drugs.
By ensuring greater access to the same substance at a lower cost,
they will greatly affect the current situation of pharmaceutical
and insurance companies, as well as patients themselves (Ornes,
2015; IMS, 2016). It was estimated that the cost-saving potential
of biosimilars could exceed 44.2 billion USD over 10 years
(Mulcahy et al., 2014). According to another source, the cost-
saving potential of biosimilars in the European Union (EU) and
theUnited States (US) could equal evenmore than 50 billion EUR
over 5 years and reach even 100 billion EUR in 2020 (IMS, 2016).
Biologics are becoming increasingly important on the
pharmaceutical market. They are listed among 10 key therapies
in the world, and their sales volumes largely increased in the
period from 2009–2014. In 2009 only 2 biologics were among 10
key therapies in the world: etanercept and infliximab (listed the
sixth and seventh, respectively). But in 2014 there were already
5 biologics: adalimumab (first), insulinum glargine (second),
etanercept (fifth), infliximab (seventh), and rituximab (tenth)
(Long, 2015). In Germany the position of biologics is even higher:
in 2014 the top 5 key therapies were biologics (adalimumab,
bevacizumab, etanercept, trastuzumab, and rituximab), and there
were 2 additional biologics, infliximab and interferon beta-1a,
listed as the ninth and tenth, respectively. There were only 3
small-molecule products listed in the top 10. Such situation has
been observed since 2009 when 5 out of the top 10 products
were biologics (adalimumab, etanercept, interferon beta-1a,
enoxaparin, and trastuzumab) (Long, 2015). Several biologics
will lose patent exclusivity between the years 2015 and 2020 (see
Table 1).
Sales of the 8 top-selling biologics which will lose patent
protection by 2020 are enormous. They equalled 42.3 billion EUR
in September 2015 in 5 EU countries (France, Germany, Italy,
Spain, United Kingdom) and in the US (IMS, 2016) and 60.3
billion USD globally in the whole US and EU (Long, 2015).
The introduction of biosimilars has increased the access
to effective treatment by reducing costs, thus significantly
increasing the use of biologics. The increase was the highest in
countries with a previously limited access to these drugs, such as
Romania, Bulgaria, and Czech Republic (IMS, 2016). The average
price reduction of biologics due to introduction of biosimilars
was 27% in the EU in general, and 50% in Romania, Bulgaria, and
Czech Republic. The average increase in sales was 16 and 263%,
respectively (IMS, 2016). The introduction of biosimilars has also
increased the number of available treatment options.
In Europe, there is no universal approach to the
reimbursement of biosimilars. Their pricing and the extent
of price reduction can vary significantly between countries. The
highest price reduction of biosimilars compared to original drugs
was observed in Germany (55%) and France (39%), while it was
lower in Scandinavian countries, ranging from 25 to 29% (IMS,
2016).
The aim of our study was to review the requirements for the
reimbursement of biosimilars in selected CEE countries as well
as to perform relative comparisons to assess differences in the
market share and reimbursement costs of biosimilars between
those countries.
MATERIALS AND METHODS
The study was conducted in a period from November 2016 to
January 2017. Experts from participating countries including
Bulgaria, Czech Republic, Croatia, Estonia, Hungary, Latvia,
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Lithuania, Poland, Slovakia, and Romania provided in-
depth data, valid for sophisticated assessment of biosimilars
environment in reference countries, their pricing and
reimbursement policy of biologics in their countries, as well as
data on coverage for specific biologics, separately for original
drugs and biosimilars. In order to facilitate comparisons between
countries, reviews were based on a standardized questionnaire
which included all necessary aspects covered by the project.
In our study, at least one leading national expert (scientist
or government official) participated, who was involved in
biosimilars pricing and reimbursement policy, representing each
of considered countries; collection as well as assessment of data
was conducted under supervision of coordinator of the whole
project.
The first part of the survey included questions on the pricing
and reimbursement of biologics in a given country, while the
second part required providing data on the reimbursement status
and level for each individual biologic drug. Reimbursement status
data are valid for the fourth quarter of the year 2016; data on
reimbursement costs of biologic drugs (separately for original
drugs and biosimilars if country-specific data was available) in
the years 2014 and 2015 were also collected along with the
corresponding data on the total pharmaceutical and public health
care budgets.
In our analysis, we included all currently approved biosimilars
(25 product names) for 10 biologic drugs: enoxaparin sodium,
epoetin alfa, epoetin zeta, etanercept, filgrastim, follitropin
alfa, infliximab, insulin glargine, somatropine, and teriparatide
according to the European Medicines Agency (EMA) official
website (European Medicines Agency, 2017).
The questionnaires were distributed and responses were
collected by e-mail. E-mail was also used to contact respondents
in case of any doubts or additional questions.
The statistical analysis of obtained data was performed. The
following values were calculated: the share of expenditure on
the reimbursement of biosimilars and original drugs separately
for each biologic and for each country, the share of expenditure
TABLE 1 | Patent expiry dates of biologics (Derbyshire, 2015).
Biologics Patent expiry date
in the EU
Patent expiry date
in the US
Humira® (adalimumab) 2018 2016
Avastin® (bevacizumab) 2022 2019
Enbrel® (etanercept) 2015 2028
Remicade® (infliximab) 2015 2018
NovoLog®/NovoRapid® (insulin aspart) 2011 2014
Lantus® (insulin glargine) 2014 2014
Avonex® (interferon beta-1a) 2015 2015
Tysabri® (natalizumab) 2015 2015
Xolair® (omalizumab) 2017 2017
Neulasta® (pegfilgrastim) 2017 2015
MabThera® (rituximab) 2013 2016
Lucentis® (ranibizumab) 2022 2020
Herceptin® (trastuzumab) 2014 2019
on reimbursement of biosimilars as percentage of the total
pharmaceutical budget and total health care budget in the year
2014 and 2015.
RESULTS
A Review of Pricing and Reimbursement of
Biosimilars in CEE Countries
Selected issues relating to the reimbursement and pricing
of biosimilars in the CEE countries were summarized in
Table 2. None of the countries were shown to have a specific
price negotiation procedure exclusively for biosimilars, except
Lithuania, which applied a specific pricing pathway for outpatient
care.
We found specific price discounts for the first or subsequent
biosimilars (or both) submitted for reimbursement in all
countries. The discount ranged from 5 to 30% of the price of
the original drug. In Hungary, the first biosimilar entering the
market has to offer a price reduction of 30% in relation to
the ex-factory price of the original product (ESzCsM Decree,
2017), the second—an additional 10% reduction of the ex-factory
price of the first biosimilar product, and the third—a further
10% reduction of the ex-factory price of the second biosimilar
product. Any additional product has to enter the market
with a lower ex-factory price than the cheapest reimbursed
product.
The reimbursement criteria for biosimilars were generally
similar to those for other generic products, and there were no
specific criteria exclusively for biosimilars in any of the countries
(see Table 2). In Bulgaria the criteria for reimbursement were
as follows: availability of an alternative medicine for the
treatment of the disease for which the medicinal product
is indicated, efficacy and therapeutic effectiveness, safety,
appropriate pharmacoeconomic indicators, as well as a positive
reimbursement status in at least 5 other EU countries1,2. In
Romania each evaluation criterion had its own number of points,
and the criteria were as follows: health technology assessment
(HTA) based on therapeutic benefit (max. 15 points), HTA
based on number of EU countries with a positive reimbursement
status (max. 25 points), Positive Assessment Report issued by
the National Agency for Medicines and Medical Devices (max.
45 points), and therapy costs—direct costs (max. 30 points). The
maximum was 145 points and conditional reimbursement is for
60–79 points (Ministry of Health, 2013, 2014).
The price of biosimilars is regulated by the tendering
system/procedure in the majority of the countries, except for
Estonia and Lithuania where it applies only to inpatient care. In
Slovakia, Poland, and Hungary, the main criterion for tendering
is price. In Czech Republic, tenders are rarely established
by the State Institute for Drug Control (SUKL) or health
insurance funds, because there is a mandatory reassessment
1Annex I and Annex II of the Positive Drug List of Bulgaria. Available online at:
www.ncpr.bg (Accessed February13, 2017).
2Ordinance on the Terms, Rules and Procedure for Regulation and Registration of
Prices for Medicinal Products/30.04.2013, Ammended and Supplemented, SG 8 of
24.01.2017. Available online at: http://www.ncpr.bg/ (Accessed February13, 2017).
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of the reimbursement level for all products within a reference
group, based on the tender offer. This means that following a
tender offer all products within the reference group will undergo
a reassessment (usually a reduction) of reimbursement based
on the tender price. However, tenders are frequently used for
inpatient drugs. In Latvia, Croatia, and Romania, tendering is not
used for biosimilars.
Therapeutic substitution, which is a change of one substance
(e.g., infliximab) for another substance (e.g., adalimumab) with
a similar therapeutic effect and indication, was allowed only at
the discretion of the physician, except for Lithuania, Latvia and
Poland, where substitution was not allowed. Interchangeability,
which means using one biosimilar in place of another one [e.g.,
Remsima (infliximab) in place of Inflectra (infliximab)], was
generally allowed but only at the discretion of the physician.
The exception was Lithuania where interchangeability was
not allowed. No legal basis for therapeutic substitution or
interchangeability of biosimilars was reported for any of the
countries.
If a given biosimilar is the first drug with a particular active
substance to be reimbursed, a full HTA dossier is obligatory in
all countries except Lithuania. If the original drug or another
biosimilar with the same active substance has already been
reimbursed, usually there is no need for full HTA documentation;
in Poland only simplified Budget Impact Analysis (BIA) should
be submitted (Kawalec and Malinowski, 2016; Panteli et al.,
2016). In Bulgaria, if there is already the same International Non-
proprietary Name (INN) on the Positive Drug List, the biosimilar
product should be evaluated by the National Council on
Prices and Reimbursement, providing the final reimbursement
decision. In Croatia only BIA is required for biosimilars, and
in certain cases, the Croatian HTA agency performs HTA
evaluation.
The timelines for pricing and reimbursement decisions
differed between the countries and ranged from 60 to 200
days, but in the majority of the countries, a 180-day deadline
for decision-making process was applied according to the EU
Transparency Directive. In Hungary (ESzCsM Decree, 2017),
it depends on the type of the procedure applied: in the case
of a standard procedure, it usually takes 90 days to make
a reimbursement decision, and in the case of a simplified
procedure—only 60 days. In Bulgaria since 2016 the procedure
for new INNs is extended to 180 days as in the reimbursement
decision process a HTA Committee is involved. Within 90 days
the HTA Committee should issue recommendation for inclusion
in the Positive Drug List. If the decision is positive, the National
Council on Prices and Reimbursement of Medicinal Products
should issue the final reimbursement decision in 90 days. In case
there is already the same INN on the Positive Drug List the
National Council on Prices and Reimbursement should issue the
reimbursement decision in 60 or 90 days like in Hungary and
Estonia, respectively (Regulation of Ministry of Social Affairs,
2017).
In all countries, except Bulgaria and Latvia which did
not provide specific information, biosimilars belong to a
homogenous group of drugs. In Estonia, the homogenous group
is made with a transitional period of 3 months. Internal reference
pricing was used in all countries, except Latvia for which this
particular data is not available.
Reimbursement Status of Biologics
We analyzed the reimbursement status of selected biologic drugs
for which biosimilars are available, separately for each country,
and indication. The level of reimbursement (the percentage of
the drug price covered by public payer) per drug and country is
shown in Table 3.
The biologic drugs were reimbursed in the majority of cases
in all countries: filgrastim for neutropenia or febrile neutropenia;
etanercept for rheumatoid arthritis, juvenile idiopathic arthritis,
psoriatic arthritis, and ankylosing spondylitis; infliximab for
all approved indications (except plaque psoriasis in Latvia);
insulin glargine for diabetes mellitus; and somatropin for growth
disturbance or growth hormone deficiency. Epoetin alfa and
epoetin zeta was not reimbursed in Estonia, while in each
other country epoetin alfa or zeta was financed from public
funds in at least one indication (no data for Lithuania).
Etanercept was not reimbursed in Latvia in the treatment of
axial spondyloarthritis and plaque psoriasis. Enoxaparin for
thromboembolic disorders of venous origin was reimbursed in all
countries except Lithuania. Follatropin alfa and teriparatide are
reimbursed inmajority of countries—only in Romania follitropin
alfa was not financed from public funds, and teriparatide
was not reimbursed in Estonia and Poland (no data for
Lithuania).
Inpatient drugs generally had 100% reimbursement
(filgrastim, etanercept, infliximab, epoetin alfa, and zeta
products), although for insulin glargine the reimbursement rates
ranged from 30 to 100%. In Hungary filgrastim, somatropin,
epoetin alfa, and zeta products were reimbursed in 100% but
a prescription fee per unit of 300 HUF (about 1 EUR) was
covered by the patient. Etanercept and infliximab products
were reimbursed in 100% in 2014 and 2015 through itemized
payment in inpatient care. The reimbursement of filgrastim
was 100% in all other countries, except Poland, where it was
diversified and depended on the way of reimbursement. In the
case of ambulatory drugs, patients had to pay a lump sum for
a package of the product, but reimbursement was 100% for
inpatient drugs. The level of reimbursement for enoxaparin
was 100% in most countries except Poland, where the patient
paid a lump sum, Latvia and Hungary, where the patient had to
pay 25 and 10% of the price, respectively. In Slovakia selected
insulin glargine, somatropin, and enoxaparin products were fully
reimbursed, and for the remaining products patients had to pay
from 18.3 to 32.3% of the price. Follitropin alfa had different
level of reimbursement across countries—from 25% in Hungary
to 100% in Latvia, Croatia, Bulgaria, and Czech Republic.
Similar situation was observed in case of teriparatide—the level
of reimbursement varied from 50% (Bulgaria for outpatients,
Latvia) to 100% (Croatia, Bulgaria for inpatients, Romania,
Czech Republic).
Reimbursement Costs
The total expenditure on the reimbursement of biologic drugs in
the CEE countries was 397,097,152 EUR in 2014 and 411,433,628
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EUR in 2015. On average, 81.8% of the value in 2014 and 78.7% of
the value in 2015 was covered by the reimbursement of original
drugs. Romania and Bulgaria were excluded from this analysis
owing to lack of information on expenditures according to the
type of drug—original or biosimilar. The shares of expenditures
on the reimbursement of biosimilars and original drugs for each
biologic in the years 2014 and 2015 are shown in Figures 1, 2,
respectively.
On average, the lowest expenditure was shown for the
reimbursement of epoetin zeta—1.8 million EUR in 2014 and
FIGURE 1 | The shares of expenditures for the reimbursement of biosimilars and original drugs for each biologic in 2014.
FIGURE 2 | The shares of expenditures for the reimbursement of biosimilars and originals for each biologic drug in 2015.
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in 2015, and the highest—for enoxaparin (97.7 million EUR and
108.9 million EUR, respectively).
Biosimilars to etanercept, enoxaparin, and teriparatide were
not reimbursed from public funds in any of the countries
either in 2014 or 2015, while biosimilars to insulin glargine and
follitropin alfa were not reimbursed in 2014. Therefore, no costs
of reimbursement of those biosimilars were observed. Among
original products, the lowest expenditure was shown for the
reimbursement of epoetin alfa in the year 2014 (4.7 million
EUR) and filgrastim in the year 2015 (4.0 million EUR) and the
highest—for enoxaparin (97.7 million EUR in the year 2014 and
108.9 million EUR in the year 2015). Among biosimilars, the
lowest reimbursement cost in 2014 was shown for epoetin zeta
(1.8 million EUR) and in 2015—for follitropin alfa (0.5 million
EUR). The highest reimbursement cost in 2014 and 2015 was
shown for filgrastim (27.9 million EUR and 29.8 million EUR,
respectively).
The shares of expenditures on the reimbursement of
biosimilars in individual countries ranged from 8.0% in Estonia
in 2014 to 38.1% in Lithuania in 2015. The data were
presented separately for the years 2014 and 2015 in Figures 3, 4,
respectively.
The highest expenditure on the reimbursement of biologic
drugs was observed for Poland (117.0 million EUR in 2014
FIGURE 3 | The shares of expenditures on the reimbursement of biosimilars in individual countries in 2014.
FIGURE 4 | The shares of expenditures on the reimbursement of biosimilars in individual countries in 2015.
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TABLE 4 | Total pharmaceutical and health care budgets in selected countries.
Country Total public pharmaceutical budget [EUR] Total public health care budget [EUR]
2014 2015 2014 2015
Slovakia 884,000,000 905,000,000 3,882,000,000 3,995,000,000
Estonia 109,753,000 112,801,000 664,071,000 712,692,000
Bulgaria 416,168,185 436,107,447 2,037,894,823 2,030,737,139
Latvia 118,930,000 124,300,000 725,013,000 765,296,000
Croatia 667,500,000 702,300,000 3,190,000,000 3,080,000,000
Lithuania 245,000,000 253,000,000 1,380,000,000 1,470,000,000
Romania 1,838,000,000 1,774,000,000 4,892,000,000 4,775,000,000
Czech Republic 1,900,000,000 2,100,000,000 9,000,000,000 9,400,000,000
Poland 2,397,729,416 2,500,319,654 15,241,155,882 16,245,277,755
Hungary 935,359, 295 1,000,955,147 5,011,650,360 5,129,812,843
and 120.0 million EUR in 2015) and the lowest—for Romania
(3.8 million EUR in 2014 and 3.7 million EUR in 2015). The
highest expenditure on the reimbursement of original drugs
was also observed for Poland (95.2 million EUR in 2014 and
94.5 million EUR in 2015), but the lowest—for Latvia (4.3
million EUR in 2014 and 5.1 million EUR in 2015). As for
the reimbursement of biosimilars, the highest expenditure was
revealed for Poland (21.8 million EUR in 2014 and 25.5 million
EUR in 2015), and the lowest for Estonia (0.7 million EUR
and 1.0 million EUR, respectively). Romania and Bulgaria
were excluded from this analysis due to lack of information
on expenditures according to the type of drug—original
or biosimilar.
The total public pharmaceutical budget and total health
care budget differed significantly between the countries. The
lowest pharmaceutical and health care budgets were observed for
Estonia and the highest—for Poland (see Table 4).
The expenditures on the reimbursement of biosimilars were
presented as the percentage of the total pharmaceutical budget
(Figure 5) and percentage of the total health care budget
(Figure 6).
The expenditures on the reimbursement of biosimilars
constituted the highest share of the total pharmaceutical budget
and total health care budget in Hungary and Slovakia (1.7
and 0.4%, respectively) and the lowest—in Croatia (0.3 and
0.1%, respectively). The expenditures on the reimbursement of
biosimilars as the share of the total pharmaceutical budget were
higher in 2015 than in 2014 in all countries, except Slovakia and
Hungary where the shares were lower in 2015. The expenditures
on the reimbursement of biosimilars as the share of the total
health care budget were also higher in 2015 than in 2014 in
all countries, again except Slovakia and Hungary where the
expenditures were higher in 2014.
DISCUSSION
Biological drugs are highly effective but also very costly. The high
price of original drugs limits access to treatment, especially in
low-income CEE countries. The widespread use of biosimilars
might significantly reduce the cost of biologic treatment, also
for individual patients. In this study we identified biologic drugs
that have their biosimilar counterparts. We also discussed issues
relating to the reimbursement and pricing of biosimilars, as well
as their reimbursement status in CEE countries.
Our review revealed that the access to biologic treatment
within specific drug groups was similar but the level of the
patient’s co-payment for particular drugs differed between the
CEE countries. For example in Bulgaria for 12 of the indications
(out of 25) biological therapy is co-paid by outpatients thus
becoming unaffordable in case of high prices. The use of
biosimilars was quite common, and the percentage of biosimilars
used in the treatment of specific disease groups increased during
the study period. No reimbursement was observed for etanercept,
insulin glargine (in 2014), follitropin alfa (in 2014), teriparatide,
and enoxaparin, which may suggest that no biosimilars to those
drugs were available in those countries. Only for filgrastim,
somatropin, and epoetin (alfa and zeta) the reimbursement costs
were higher for biosimilars than for original drugs. For the
remaining drugs, the share of reimbursement costs of biosimilars
in the total reimbursement costs of a biologic drug did not
exceed 26%.
The shares of expenditures on the reimbursement of
biosimilars in each country were similar and ranged from 8 to
32% in 2014 and from 12 to 38% in 2015. Expenditures on the
reimbursement of biosimilars constituted from 0.3 to 1.7% of
the total pharmaceutical budget in 2014 and was similar in the
year 2015 (from 0.6 to 1.7%), but the average value was higher
in the year 2015 (1.1% in the year 2014 compared with 1.2% in
the year 2015). The shares of expenditures on the reimbursement
of biosimilars in the total health care budget were also similar
between the year 2014 and 2015—from 0.06% to 0.4% in 2014
and 2015, but again the average value was higher in the year 2015
(0.20% in the year 2014 compared with 0.22% in the year 2015).
In Hungary it is mandatory to use the cheapest available
biological product in newly treated patients. For erythropoietin
(EPO) and granulocyte colony-stimulating factors (GCSF), the
so called biosimilar bids were introduced in 2012 (Hornyák
et al., 2014). They are organized annually, and in each group of
biologics the preferred drugs are those with the lowest price. As
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FIGURE 5 | Expenditures on the reimbursement of biosimilars as percentage of the total pharmaceutical budget.
FIGURE 6 | Expenditures on the reimbursement of biosimilars as percentage of the total health care budget.
these products have 100% reimbursement, there is a prescription
fee of only 300 Hungarian forints (HUF). Preferred drugs can be
those with a price that is a maximum of 10% higher than the
price of the reference product (i.e., the cheapest). Drugs with a
price that is between 10 and 30% higher than that of the reference
products are required to compensate the payer for the increased
price with payback and are associated with a co-payment between
1,500 and 3,500 HUF. Increased co-payment is therefore a
disincentive for patients to use these products. Drugs with a
price that is 30% higher than that of the reference products are
removed from the reimbursement list (i.e., positive list) 4 months
after the biosimilar bid. Until then, they have a co-payment
of 3,500 HUF. This allows some time for the patient and the
treating physician to switch to a preferred product. Additionally,
physicians are required to prescribe preferred biologics in a
minimum 40% of the overall number of prescriptions.
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In Estonia, inpatient drugs, such as filgrastim, infliximab, and
etanercept, are reimbursed by the hospital, and it is hospital
authorities who decide, usually through tendering procedure,
which products and at what prices will be acquired. The data are
usually confidential and hospitals do not have to officially report
which products they use in provision of health care services.
Therefore, there are limited data on the reimbursement costs for
Estonia, both for original drugs and biosimilars.
In Romania, the rate of reimbursement for biosimilar
products is 100% of the reference price, that is, in general, the
lowest price of products with the same active substance, the
same strength and the same pharmaceutical form (biosimilars)
available for reimbursement. The physician can choose a specific
product and the difference between the drug’s price and the
reference price is paid by patient, but in the case of biosimilars
this difference is 0.
In Croatia the pricing and reimbursement process for
biosimilars may sometimes require cost-effectiveness or cost-
utility analysis3. In Latvia cost-minimization analysis and
budget impact analysis are needed, while in Czech Republic
an abbreviated clinical dossier should be presented, without
economic evidence. In Czech Republic and Slovakia physicians
prefer to treat new patients with biosimilars, while previously
treated patients usually remain on the original product.
We performed a systematic review of medical databases
(Medline via Pubmed and the Scientific Presentations database
of International Society of Pharmaceoeconomics and Outcomes
Research [ISPOR]) to identify relevant studies referring to
biosimilar drug policy in CEE countries. However, we found
no publications in line with the scope of our study, which
emphasizes the novelty of our research. The review revealed only
some papers on issues relating to the cost and reimbursement
of biosimilars, but focusing mainly on the budget impact of
biosimilar reimbursement or including a simplified discussion of
an individual aspect (e.g., pricing) of biosimilar drug policy in
individual CEE countries.
Hornyák et al. (2015) analyzed biosimilar bids of the
Hungarian National Health Insurance Fund Administration
(NHIFA) for colony-stimulating factor (CSF) products. Before
the biosimilar bid, the NHIFA spent 7.49 billion HUF for health
insurance reimbursement of CSF products, which decreased by
44% to 4.19 billion HUF in the first year after the bid. The
analyses of the Hungarian price competition bid for biosimilar
products showed a minor decline in the number of patients
on treatment with CSF products, while the health insurance
reimbursement of these drugs significantly decreased (Hornyák
et al., 2014). Similar conclusions were drawn from the analysis of
the biosimilar bids of the NHIFA for EPO products. The NHIFA
spent 2.33 billion HUF for health insurance reimbursement of
EPO products, which decreased by 47% to 1.23 billion HUF in
the first year after the bid. Thus, the price competition bid of
biosimilar products showed a health insurance reimbursement
of these drugs to have significantly decreased (Nagy et al.,
2015).
3Available online at: http://www.hzzo.hr/zdravstveni-sustav-rh/trazilica-za-
lijekove-s-vazecih-lista/arhiva-liste-lijekova (Accessed February13, 2017).
We also identified an abstract (Vogler et al., 2016) presenting
the results of a survey analyzing the possible differences between
pricing policies for generics and for biosimilar medicines in
European countries including 25 EU countries (all except Ireland,
Italy, and Luxembourg) as well as Albania, Belarus, Iceland,
Norway, Serbia, Russia, Turkey, and Ukraine. While 23 of the 33
countries set the price of the generic in relation to the price of
the originator, only 13 countries reported to do so for biosimilar
medicines. Usually, the price difference between the biosimilar
and originator medicine was set at a lower percentage rate than
that between the generic and originator (e.g., 30%—generics,
15%—biosimilars in Croatia; 50%—generics, 30%—biosimilars
in Lithuania; 35%—generics, 20%—biosimilars in Romania).
It occurred that only Austria, Latvia, and Turkey applied the
same price difference for generic and biosimilar medicines. The
Netherlands have been tendering for generics in the outpatient
sector during the last decade, but biosimilars have been included
in tenders only recently. The authors concluded that European
countries tend to apply similar pricing policies for generic and
biosimilar medicines (Vogler et al., 2016).
Another study (Brodszky et al., 2014, 2016) analyzed the
budget impact of introducing biosimilar infliximab for the
treatment of patients with Crohn disease (CD) in the health care
systems of 6 CEE countries: Bulgaria, Czech Republic, Hungary,
Poland, Romania, and Slovakia. This budget impact model
estimated the potential impact of biosimilar infliximab on health
care budget over 3-year timeframe from the third-party payer
perspective. The model tracked movement of the population
of patients with CD between main states: (1) immune therapy,
(2) infliximab, (3) biosimilar infliximab, and (4) adalimumab.
Switching between biologics and biosimilar infliximab was also
considered. A price difference of 25% was assumed for biosimilar
infliximab compared to the originator. Budget impact was
calculated as a difference in the total cost of scenarios with
and without biosimilar infliximab. Over the 3-year period,
with gradually interchanging 80% of infliximab to biosimilar,
infliximab was expected to lead to a net benefit of 16,635,000 EUR
compared with the scenario in which biosimilar infliximab would
not be available. In the scenario in which interchangeability
was not allowed, the budget savings amounted to 7,842,000
EUR. It was revealed that if budget savings were spent on the
reimbursement of additional biosimilar infliximab treatments,
∼722–1,530 additional patients with CD could be treated in the 6
countries (Brodszky et al., 2016). Based on these calculations, the
introduction of biosimilar infliximab treatment for CD in CEE
countries should bring about substantial cost savings or increase
the number of patients with access to biologic therapy (Brodszky
et al., 2014, 2016).
Rovira et al. (2013) described the development of biosimilars
in 24 EU countries, Norway and Switzerland. Authors tried
to identify the key parameters associated with biosimilars
market dynamics and included three molecules as references:
somatropin, epoetin, filgrastim. The results of this analysis
showed that the market share of biosimilars for included
molecules has risen rapidly in the years from 2007 to 2010. The
key drivers responsible for market dynamics were: generics price
control policy, countries’ gross national income and expenditure
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on health, pharmacists’ generics substitution andmedicines’ price
level index. Introduction of biosimilars resulted in reduction of
biologics’ cost, however this reduction seems to be smaller than
for conventional generics.
Authors of another study (Remuzat et al., 2017) also tried to
identify the key drivers for market penetration of biosimilars in
Europe. Ten EUmember states were included in the analysis and
20 biosimilars. It was concluded, that incentive policies applied to
biosimilars and biosimilars’ uptakes were heterogeneous across
analyzed countries. Incentive policies and the date of first
biosimilarmarket entry were positively correlated with biosimilar
uptake, while pharmaceutical expenditure per capita and the
highest generic uptake were inversely correlated with biosimilar
uptake. Also the average generic price discount over originator
and the number of biosimilars seemed to influence the biosimilar
uptake, however biosimilar price discounts had no impact on the
uptake.
Grabowski et al. in their study (Grabowski et al., 2014)
analyzed the experiences with biosimilars to epoetin alfa
and filgrastim in 5 EU countries. One major finding was
that although the EU has a common regulatory system for
approving biosimilars, differences in reimbursement practices
and incentives as well as variations in medical practices are
observed across countries. It was observed that biosimilar price
discounts were likely to be modest compared to generics.
Another finding was that cost savings from the introduction of
biosimilars in the European countries have been tempered by
the fact that competition has been limited to the first-generation
reference products. Dynamic competition through the market
entry of next-generation biologics is an important consideration
in analyzing the market impact of biosimilars and their potential
savings to the health-care system.
In countries of the EU as well as outside the EU evaluations
on costs of biologic drugs were also performed (Jakovljevic,
2014) but with no sophisticated analyses of market share and
reimbursement costs between original biologics and biosimilars
corresponding to results of our study.
CONCLUSIONS
Our study revealed that biosimilars significantly influenced
the reimbursement systems in the selected CEE countries.
Expenditures on the reimbursement of biosimilars are increasing,
and the access of patients to this type of treatment is improving.
The share of expenditures on the reimbursement of biosimilars in
the considered CEE countries increased during the study period,
along with an increase in expenditures on the reimbursement
of biosimilars as percentage of the total pharmaceutical budget.
The considered CEE countries are similar in terms of the
requirements for the pricing and reimbursement of biosimilars.
AUTHOR CONTRIBUTIONS
PK conceived the conception and design of the study, including
protocol and questionnaires preparation, and coordinated the
project. PK contributed in acquisition of data. PK and ES carried
out the data management, statistical analysis, interpretation of
data and prepared the draft of the manuscript. TT, JS, AT, MD,
GP, ZR, AM, AH, and PD collected and provided input data
for corresponding countries. All authors contributed to editing
the manuscript and approved the final version submitted for
publication. PK is the guarantor.
ACKNOWLEDGMENTS
The study was self-financed. The authors would like to thank
Karoline Garuoliene for providing relevant data for our project
relating to Lithuania.
REFERENCES
Brodszky, V., Gulacsi, L., Balogh, O., Baji, P., Rencz, F., and Péntek, M. (2014).
Budget impact analysis of biosimilar infliximab for the treatment of crohn’s
disease in six central eastern European countries. Value Health 17:A364.
doi: 10.1016/j.jval.2014.08.805
Brodszky, V., Rencz, F., Péntek, M., Baji, P., Lakatos, P. L., and Gulácsi,
L. (2016). A budget impact model for biosimilar infliximab in Crohn’s
disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania,
and Slovakia. Expert Rev. Pharmacoecon. Outcomes Res. 16, 119–125.
doi: 10.1586/14737167.2015.1067142
Derbyshire, M. (2015). Patent expiry dates for best-selling biological. Gene.
Biosimilars Initiat. J. 4, 178–179. doi: 10.5639/gabij.2015.0404.040
ESzCsM Decree (2017). 32/2004. (IV. 26.) ESzCsM Decree, Concerning the
Reimbursement of Medicinal Products. Available online at: http://net.jogtar.hu/
jr/gen/hjegy_doc.cgi?docid=A0400032.ESC (Accessed February 13, 2017).
European Medicines Agency (2017). European Public Assessment
Reports. Available online at: http://www.ema.europa.eu/ema/index.
jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=
WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=
true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&
searchType=name&taxonomyPath=&treeNumber=&searchGenericType=
biosimilars&genericsKeywordSearch=Submit (Accessed February 13, 2017).
Grabowski, H., Guha, R., and Salgado, M. (2014). Biosimilar competition: lessons
from Europe. Nat. Rev. Drug Discov. 13, 99–100. doi: 10.1038/nrd4210
Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., Ágoston, I., Csákvári, T., et al.
(2014). Experiences with price competition of biosimilar drugs in Hungary.
Acta Pharm. Hung. 84, 83–87. doi: 10.1016/j.jval.2014.08.1018
Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., Ágoston, I., Csákvári, T.,
et al. (2015). Experiences with price competition of biosimilar drugs in
hungary in case of colony-stimulating factor products. Value Health 18:A477.
doi: 10.1016/j.jval.2015.09.1285
IMS (2016). Delivering on the Potential of Biosimilar Medicines. The Role of
Functioning Competitive Markets. IMS Institute for Healthcare Informatics.
Available online at: http://www.imshealth.com/files/web/IMSH%20Institute/
Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_
2016.pdf (Accessed February 13, 2017).
Jakovljevic, M. B. (2014). Oncology monoclonal antibodies expenditure trends
and reimbursement projections in the emerging Balkan market. Farmeconomia
Health Econ. Ther. Pathways 15, 27–32. doi: 10.7175/fe.v15i1.909
Kawalec, P., and Malinowski, K. P. (2016). Relating Health Technology
Assessment recommendations and reimbursement decisions in Poland in
years 2012-2014, a retrospective analysis. Health Policy 120, 1240–1248.
doi: 10.1016/j.healthpol.2016.09.021
Long, D. (2015). “Perspective on the evolving biosimilars landscape,” in HDMA
Distribution Management Conference and EXPO (Orlando, FL).
Frontiers in Pharmacology | www.frontiersin.org 13 June 2017 | Volume 8 | Article 288
Kawalec et al. Biosimilars Policy in CEE Countries
Ministry of Health (2011). [Decree No. 422/2011 of the Ministry of Health of the
Slovak Republic on the Details of the Pharmacoeconomic Analysis of Medicine]
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